| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,869 |
4,547 |
$3.57M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
5,947 |
5,688 |
$1.74M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,727 |
1,568 |
$1.37M |
| 71045 |
Radiologic examination, chest; single view |
2,524 |
2,331 |
$319K |
| 87428 |
|
2,636 |
2,546 |
$218K |
| 59025 |
Fetal non-stress test |
588 |
371 |
$173K |
| 80053 |
Comprehensive metabolic panel |
7,566 |
6,688 |
$105K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
3,130 |
3,043 |
$103K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,832 |
1,677 |
$96K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
8,430 |
7,415 |
$91K |
| 87400 |
|
2,179 |
2,109 |
$87K |
| 36415 |
Collection of venous blood by venipuncture |
12,535 |
8,023 |
$40K |
| 70450 |
Computed tomography, head or brain; without contrast material |
638 |
608 |
$30K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
254 |
245 |
$28K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
770 |
732 |
$27K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
120 |
117 |
$23K |
| 84484 |
|
1,599 |
1,332 |
$19K |
| 87147 |
|
867 |
843 |
$17K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
12 |
12 |
$15K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
111 |
109 |
$15K |
| 81025 |
|
406 |
384 |
$14K |
| 83690 |
|
1,063 |
958 |
$14K |
| 81001 |
|
2,925 |
2,681 |
$13K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
608 |
401 |
$11K |
| 86738 |
|
211 |
203 |
$10K |
| 83735 |
|
339 |
330 |
$10K |
| 85730 |
|
1,312 |
1,202 |
$9K |
| 31720 |
|
33 |
32 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
559 |
262 |
$8K |
| 83605 |
|
590 |
536 |
$7K |
| 85610 |
|
1,542 |
1,402 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
588 |
527 |
$5K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
567 |
529 |
$5K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
790 |
735 |
$5K |
| 82150 |
|
232 |
223 |
$4K |
| 84100 |
|
328 |
307 |
$4K |
| 71046 |
Radiologic examination, chest; 2 views |
29 |
26 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
596 |
492 |
$3K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
41 |
41 |
$3K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
19 |
12 |
$3K |
| 83880 |
|
590 |
535 |
$3K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
31 |
25 |
$3K |
| 87420 |
|
55 |
54 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
314 |
248 |
$2K |
| 82550 |
|
186 |
170 |
$2K |
| 86140 |
|
239 |
223 |
$2K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
498 |
455 |
$2K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
691 |
673 |
$2K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
18 |
16 |
$2K |
| 85651 |
|
90 |
86 |
$1K |
| 82077 |
|
13 |
12 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
900 |
878 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
41 |
39 |
$778.55 |
| 83615 |
|
63 |
53 |
$658.73 |
| 84550 |
|
109 |
93 |
$511.47 |
| 83930 |
|
15 |
13 |
$438.56 |
| 87040 |
|
107 |
91 |
$395.92 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
677 |
617 |
$328.38 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
364 |
356 |
$277.63 |
| 82803 |
|
31 |
27 |
$250.04 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
13 |
12 |
$241.96 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
591 |
526 |
$220.71 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
515 |
470 |
$203.20 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
108 |
108 |
$202.80 |
| 81003 |
|
68 |
66 |
$186.21 |
| J3490 |
Unclassified drugs |
51 |
46 |
$162.46 |
| 80061 |
Lipid panel |
545 |
514 |
$126.80 |
| 36600 |
|
15 |
13 |
$93.24 |
| J2704 |
Injection, propofol, 10 mg |
106 |
105 |
$79.95 |
| 85027 |
|
236 |
228 |
$54.84 |
| 87077 |
|
113 |
106 |
$27.37 |
| 87186 |
|
113 |
105 |
$22.04 |
| 80047 |
|
13 |
12 |
$20.14 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
122 |
117 |
$19.97 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
34 |
31 |
$18.16 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
31 |
25 |
$13.78 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
97 |
93 |
$12.76 |
| 85014 |
|
16 |
14 |
$6.50 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
13 |
12 |
$6.42 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
235 |
223 |
$4.68 |
| 82248 |
|
14 |
14 |
$4.50 |
| 80164 |
|
21 |
18 |
$0.00 |
| 82962 |
|
168 |
141 |
$0.00 |
| 87070 |
|
26 |
24 |
$0.00 |
| 82607 |
|
13 |
13 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
27 |
25 |
$0.00 |